Revvity, Inc. (RVTY) स्टॉक विश्लेषण

कंपनी का अवलोकन

Revvity, Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry by providing comprehensive health sciences solutions, technologies, and services to its customer base. The firm's portfolio encompasses a wide array of instruments, reagents, software, and subscriptions, alongside detection and imaging technologies that support early-stage research and clinical applications. This organization employs approximately 11,000 individuals and maintains a substantial market capitalization of $10.11 billion, reflecting its established position in the financial landscape. The annual revenue generated over the trailing twelve months stands at $2.86 billion, which, combined with the significant market cap, indicates that Revvity, Inc. commands a large-scale presence and holds considerable influence within the specialized diagnostic equipment and research services market.

वित्तीय स्वास्थ्य

Revvity, Inc. reported a trailing twelve-month net income of $239.88 million, derived from a total revenue base of $2.86 billion, while generating an EBITDA of $840.93 million; the substantial gap between revenue and net income highlights a cost structure where operational expenses, including cost of goods sold and administrative costs, consume a significant portion of top-line earnings before reaching the bottom line. The company produced $523.28 million in free cash flow, a metric that signifies strong operational efficiency and provides the management team with substantial financial flexibility to fund capital expenditures, reduce debt obligations, or pursue strategic acquisitions without relying heavily on external financing. Profitability analysis reveals a gross margin of 54.8%, indicating efficient production and pricing strategies, an operating margin of 20.1% which reflects effective control over operating expenses, and a profit margin of 8.4% that demonstrates the final conversion of revenue into net earnings after all costs. Regarding balance sheet leverage, Revvity holds $919.86 million in cash against total debt of $3.40 billion, resulting in a debt-to-equity ratio of 46.87, which suggests a leveraged balance sheet where long-term obligations exceed liquid assets, requiring steady cash flow generation to meet obligations. Short-term liquidity is supported by a current ratio of 1.68, meaning the company possesses $1.68 in current assets for every dollar of current liabilities, indicating a comfortable ability to cover immediate financial commitments. Return on equity stands at 3.2% and return on assets is 2.2%, metrics that reveal the current level of capital efficiency and suggest that the company's management is utilizing shareholder equity and total assets to generate relatively modest returns compared to historical benchmarks or high-growth peers.

मूल्यांकन आकलन

The trailing twelve-month P/E ratio is 43.88, while the forward P/E is significantly lower at 15.07, implying that the market currently prices in a substantial increase in future earnings growth that is not yet reflected in historical performance. The price-to-book ratio of 1.40 indicates that the stock trades at a premium of 40% over its book value, suggesting that investors value the company's intangible assets, brand, and future growth prospects more highly than its tangible net worth. Alternative valuation metrics provide further context, with a price-to-sales ratio of 3.54 and an EV/EBITDA of 14.97, which together suggest that the market is willing to pay a premium for every dollar of sales and earnings, consistent with a mature but still growing healthcare technology firm. The stock has exhibited volatility within its trading range, hitting a 52-week high of $118.30 and a 52-week low of $81.36, placing the current valuation context within a band where the stock has experienced significant movement relative to its recent historical extremes. The beta value of 1.13 indicates that the stock's price volatility is 13% higher than the broader market, meaning that Revvity, Inc. tends to amplify market movements and may experience larger swings during periods of market uncertainty or optimism.

Growth & Income

Revenue growth over the past year stands at 5.9%, while earnings growth has accelerated to 12.5%, indicating that the company's profitability is expanding at a faster rate than its top-line sales, which often suggests improving operational leverage or margin expansion. The company offers a dividend yield of 0.3% with a payout ratio of 13.6%, a low payout level that suggests the firm retains the majority of its earnings to fund operations, research development, and debt servicing rather than distributing them to shareholders. Given the relatively high debt levels and the modest return on equity, the low payout ratio appears conservative and sustainable, ensuring that the dividend does not compromise the company's ability to meet its financial obligations or invest in necessary technologies. Overall, Revvity, Inc. presents a growth profile characterized by double-digit earnings expansion and a cautious income approach, positioning the asset for investors seeking exposure to the diagnostics sector with a focus on capital preservation alongside moderate yield generation.